MET and neoplasm: In the TATTON study, however, no major difference in efficacy was evident based on the type MET assay used, that is, MET amplification by FISH (MET/CEP7 ratio ≥2) or next-generation sequencing (≥20% tumor cells, coverage of ≥200 × sequencing depth and ≥5 copies of MET over tumor ploidy), MET polysomy by FISH (copy number ≥5 if MET/CEP7 ratio is <2) or MET protein expression by tissue IHC (MET +3 expression in ≥50% of tumor cells; ref. 19).